🎉 M&A multiples are live!
Check it out!

Biofrontera Valuation Multiples

Discover revenue and EBITDA valuation multiples for Biofrontera and other public comps.

See Biofrontera Valuation Multiples

Biofrontera Overview

About Biofrontera

Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.


Founded

1997

HQ

Germany
Employees

110

Website

biofrontera.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$11.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Biofrontera Financials

Biofrontera has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Biofrontera achieved revenue of $33.6M and an EBITDA of -$1.4M.

Biofrontera expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Biofrontera valuation multiples based on analyst estimates

Biofrontera P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $26.8M $33.6M n/a n/a XXX
Gross Profit $25.9M $21.9M $27.1M XXX XXX
Gross Margin 97% 65% NaN% XXX XXX
EBITDA -$44.1M -$1.4M n/a n/a XXX
EBITDA Margin -164% -4% NaN% NaN% XXX
Net Profit $39.9M -$46.0M -$0.4M XXX XXX
Net Margin 149% -137% NaN% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Biofrontera Stock Performance

As of February 7, 2025, Biofrontera's stock price is EUR 2 (or $2).

Biofrontera has current market cap of EUR 14.0M (or $14.6M), and EV of EUR 11.4M (or $11.9M).

See Biofrontera trading valuation data

Biofrontera Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$11.9M $14.6M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Biofrontera Valuation Multiples

As of February 7, 2025, Biofrontera has market cap of $14.6M and EV of $11.9M.

Biofrontera's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Biofrontera's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Biofrontera and 10K+ public comps

Biofrontera Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $11.9M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Biofrontera Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Biofrontera Valuation Multiples

Biofrontera's NTM/LTM revenue growth is n/a

Biofrontera's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Biofrontera's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Biofrontera's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Biofrontera and other 10K+ public comps

Biofrontera Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 23% XXX XXX XXX XXX
G&A Expenses to Revenue 19% XXX XXX XXX XXX
R&D Expenses to Revenue 24% XXX XXX XXX XXX
Opex to Revenue 66% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Biofrontera Public Comps

See valuation multiples for Biofrontera public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Biofrontera M&A and Investment Activity

Biofrontera acquired  XXX companies to date.

Last acquisition by Biofrontera was  XXXXXXXX, XXXXX XXXXX XXXXXX . Biofrontera acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Biofrontera

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Biofrontera

When was Biofrontera founded? Biofrontera was founded in 1997.
Where is Biofrontera headquartered? Biofrontera is headquartered in Germany.
How many employees does Biofrontera have? As of today, Biofrontera has 110 employees.
Is Biofrontera publicy listed? Yes, Biofrontera is a public company listed on ETR.
What is the stock symbol of Biofrontera? Biofrontera trades under B8FK ticker.
When did Biofrontera go public? Biofrontera went public in 2007.
Who are competitors of Biofrontera? Similar companies to Biofrontera include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Biofrontera? Biofrontera's current market cap is $14.6M
Is Biofrontera profitable? Yes, Biofrontera is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.